. 2001 Nov;159(5):1861–1868. doi: 10.1016/s0002-9440(10)63032-5

Table 2.

Relative and Absolute Counts of PB Lymphocytes, LGL, and Expanded Vβ-Families in Patients with Persistent Expansions of CD4⁺ and CD8^+bright LGL According to the Presence or Not of a Monoclonal Expansion of PB T Cells by Molecular Techniques

	Expansions of CD8^+bright LGL			Expansions of CD4⁺ LGL
		Polyclonal/oligoclonal n = 34	Monoclonal n = 38	P value	Polyclonal/oligoclonal n = 6	Monoclonal n = 20	P value
Number of PB lymphocytes× 10⁹/L	3.1± 2.3 (2.4) (1.0–13.4)	5.9± 3.6 (5.0) (1.1–18.3)	.0001	3.2 ± 2.6 (2.7) (0.9–8.3)	7.1± 4.2 (6.5) (1.4–17.3)	.028
Number of total PB CD8^+bright or CD4⁺ T cells× 10⁶/L	1398± 1446 (842) (363–8080)	4178± 3520 (3312) (572–17755)	.0001	1791± 1420 (1551) (492–4467)	5063± 3161 (4633) (491–11479)	.025
Number of total PB CD8^+bright or CD4⁺ LGL× 10⁶/L	1070± 1288 (607) (225–7111)	3892± 3517 (3146) (481–17577)	.0001	678± 446 (618) (280–1519)	4455± 3049 (4309) (123–11020)	.003
Percentage of total PB CD8^+bright or CD4⁺ LGL	68± 15 (67) (31–97)	90 ± 8 (92) (73–99)	.0001	46± 22 (38) (20–76)	81± 18 (88) (25–96)	.001
Number of cases with expansions of one or more TCR-Vβ families (%)	31/34 (91%)	37/38 (97%)	N.S.	6/6 (100%)	20/20 (100%)	N.S.
Number of cases showing expansions of more than one TCR-Vβ families (%)	18/34 (53%)	3/38 (8%)	.001	1/6 (17%)	1/20 (5%)	N.S.
Number of cases with at least one Vβ expansion > 40%	5/34 (15%)	36/38 (95%)	.0001	3/6 (50%)	18/20 (90%)	.006
Highest Vβ expansion	22± 12 (21) (4–47)	74± 17 (79) (27–96)	.0001	34± 19 (32) (13–58)	75± 22 (83) (24–96)	.001
Ratio between the highest Vβ expansion and the % of LGL within CD8^+bright or CD4⁺ T-cells	0.35± 0.18 (0.33) (0.07–0.66)	0.82± 0.16 (0.87) (0.31–1.00)	.0001	0.75± 0.21 (0.78) (0.38–0.99)	0.91± 0.14 (0.97) (0.41–1.00)	.028

Results are presented as mean ± standard deviation, median (in brackets), and range (italic, in brackets). N.S.: no significant differences.